Journal of Thrombosis and Thrombolysis

, Volume 37, Issue 3, pp 279–286 | Cite as

Prednisone versus high-dose dexamethasone for untreated primary immune thrombocytopenia. A retrospective study of the Japan Hematology & Oncology Clinical Study Group

  • Kana Sakamoto
  • Hideki Nakasone
  • Shigeharu Tsurumi
  • Ko Sasaki
  • Kinuko Mitani
  • Michiko Kida
  • Akira Hangaishi
  • Kensuke Usuki
  • Ayako Kobayashi
  • Ken Sato
  • Mariko Karasawa-Yamaguchi
  • Koji Izutsu
  • Yasushi Okoshi
  • Shigeru Chiba
  • Yoshinobu Kanda
Article

Abstract

High-dose dexamethasone (HDD) has been shown to be an effective initial treatment for immune thrombocytopenia (ITP), but it is not clear whether HDD offers any advantages over conventional-dose prednisone (PSL). We retrospectively compared the efficacy and toxicity of HDD and PSL for newly diagnosed ITP. The response was evaluated according to the International Working Group (IWG) criteria. We analyzed data from 31 and 69 patients in the HDD and PSL groups, respectively. There were no significant differences in patient characteristics between the two groups except for the incidence of the eradication of Helicobacter pylori. The response rate was better in the HDD group (42.7 vs. 28.4 %), and this difference was statistically significant when adjusted for other factors including the eradication of H. pylori. In the HDD group, a response was achieved earlier (28 vs. 152 days in median) and steroids were more frequently discontinued at 6 months (64.5 vs. 37.7 %). Among patients who achieved a response, there was no significant difference in the incidence of loss of response. There were no significant differences in the rate of adverse events, transition to chronic ITP, and splenectomy. In conclusion, HDD might enable the early cessation of steroids without a loss of response.

Keywords

Immune thrombocytopenia Prednisone High dose dexamethasone Response rate Clinical management 

References

  1. 1.
    Cines DB, Bussel JB, Liebman HA, Luning Prak ET (2009) The ITP syndrome: pathogenic and clinical diversity. Blood 113:6511–6521PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kühne T, Ruggeri M, George JN (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113:2386–2393PubMedCrossRefGoogle Scholar
  3. 3.
    Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ (2010) International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 115:168–186PubMedCrossRefGoogle Scholar
  4. 4.
    Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA (2011) The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 117:4190–4207PubMedCrossRefGoogle Scholar
  5. 5.
    Bellucci S, Charpak Y, Chastang C, Tobelem G (1988) Low doses v conventional doses of corticoids in immune thrombocytopenic purpura (ITP): results of a randomized clinical trial in 160 children, 223 adults. Blood 71:1165–1169PubMedGoogle Scholar
  6. 6.
    Cines DB, Blanchette VS (2002) Immune thrombocytopenic purpura. N Engl J Med 346:995–1008PubMedCrossRefGoogle Scholar
  7. 7.
    George JN, Harake MA, Raskob GE (1994) Chronic idiopathic thrombocytopenic purpura. N Engl J Med 331:1207–1211PubMedCrossRefGoogle Scholar
  8. 8.
    George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, Blanchette VS, Bussel JB, Cines DB, Kelton JG, Lichtin AE, McMillan R, Okerbloom JA, Regan DH, Warrier I (1996) Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 88:3–40PubMedGoogle Scholar
  9. 9.
    Mazzucconi MG, Francesconi M, Fidani P, Di Nucci G, Gandolfo GM, Afeltra A, Masala C, Di Prima M, Rocchi G, Resta S (1985) Treatment of idiopathic thrombocytopenic purpura (ITP). Results of a multicentric protocol. Haematologica 70:329–336PubMedGoogle Scholar
  10. 10.
    Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A (2001) Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 97:2549–2554PubMedCrossRefGoogle Scholar
  11. 11.
    Cheng Y, Wong RS, Soo YO, Chui CH, Lau FY, Chan NP, Wong WS, Cheng G (2003) Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 349:831–836PubMedCrossRefGoogle Scholar
  12. 12.
    Mazzucconi MG, Fazi P, Bernasconi S, De Rossi G, Leone G, Gugliotta L, Vianelli N, Avvisati G, Rodeghiero F, Amendola A, Baronci C, Carbone C, Quattrin S, Fioritoni G, D’Alfonso G, Mandelli F, Gruppo Italiano Malattie EMatologiche dell’Adulto (GIMEMA) Thrombocytopenia Working Party (2007) Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 109:1401–1407PubMedCrossRefGoogle Scholar
  13. 13.
    Borst F, Keuning JJ, van Hulsteijn H, Sinnige H, Vreugdenhil G (2004) High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults. Ann Hematol 83:764–768PubMedCrossRefGoogle Scholar
  14. 14.
    Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, Vianelli N, Defina M, Tieghi A, Amadori S, Campagna S, Ferrara F, Angelucci E, Usala E, Cantoni S, Visani G, Fornaro A, Rizzi R, De Stefano V, Casulli F, Battista ML, Isola M, Soldano F, Gamba E, Fanin R (2010) Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 115:2755–2762PubMedCrossRefGoogle Scholar
  15. 15.
    Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154CrossRefGoogle Scholar
  16. 16.
    Scrucca L, Santucci A, Aversa F (2007) Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 40:381–387PubMedCrossRefGoogle Scholar
  17. 17.
    Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458Google Scholar
  18. 18.
    Apostolidis J, Tsandekidi M, Kousiafes D, Pagoni M, Mitsouli C, Karmiris T, Bakiri M, Karakasis D, Harhalakis N, Nikiforakis E (2001) Short-course corticosteroid-induced pulmonary and apparent cerebral aspergillosis in a patient with idiopathic thrombocytopenic purpura. Blood 98:2875–2877PubMedCrossRefGoogle Scholar
  19. 19.
    Andersen JC (1994) Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med 330:1560–1564PubMedCrossRefGoogle Scholar
  20. 20.
    Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG (2007) Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 146:25–33PubMedCrossRefGoogle Scholar
  21. 21.
    Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, Bussel JB (2004) The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 125:232–239PubMedCrossRefGoogle Scholar
  22. 22.
    Garcia-Chavez J, Majluf-Cruz A, Montiel-Cervantes L, Esparza MG, Vela-Ojeda J, Group MHS (2007) Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: A long-term follow-up analysis. Ann Hematol 86:871–877PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Stasi R, Pagano A, Stipa E, Amadori S (2001) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98:952–957PubMedCrossRefGoogle Scholar
  24. 24.
    Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J, Wasser JS, Wiznitzer I, Kelly R, Chen CF, Nichol JL (2006) AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 355:1672–1681PubMedCrossRefGoogle Scholar
  25. 25.
    Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM (2007) Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 357:2237–2247PubMedCrossRefGoogle Scholar
  26. 26.
    Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, Stone N, Arning M (2009) Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 373:641–648PubMedCrossRefGoogle Scholar
  27. 27.
    Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB (2011) Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 377:393–402PubMedCrossRefGoogle Scholar
  28. 28.
    Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL (2009) Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 113:2161–2171PubMedCrossRefGoogle Scholar
  29. 29.
    Khellaf M, Michel M, Quittet P, Viallard JF, Alexis M, Roudot-Thoraval F, Cheze S, Durand JM, Lefrère F, Galicier L, Lambotte O, Panelatti G, Slama B, Damaj G, Sebahoun G, Gyan E, Delbrel X, Dhedin N, Royer B, Schleinitz N, Rossi JF, Mahévas M, Languille L, Bierling P, Godeau B (2011) Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood 118:4338–4345PubMedCrossRefGoogle Scholar
  30. 30.
    Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrère F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL (2008) Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 371:395–403PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Kana Sakamoto
    • 1
  • Hideki Nakasone
    • 1
  • Shigeharu Tsurumi
    • 2
  • Ko Sasaki
    • 2
  • Kinuko Mitani
    • 2
  • Michiko Kida
    • 3
  • Akira Hangaishi
    • 3
  • Kensuke Usuki
    • 3
  • Ayako Kobayashi
    • 4
  • Ken Sato
    • 4
  • Mariko Karasawa-Yamaguchi
    • 5
  • Koji Izutsu
    • 5
  • Yasushi Okoshi
    • 6
  • Shigeru Chiba
    • 6
  • Yoshinobu Kanda
    • 1
  1. 1.Division of HematologySaitama Medical Center, Jichi Medical UniversitySaitamaJapan
  2. 2.Department of Hematology and OncologyDokkyo Medical UniversityTochigiJapan
  3. 3.Division of HematologyNTT Kanto Medical CenterTokyoJapan
  4. 4.Division of Hematology, Department of Internal MedicineNational Defense Medical CollageSaitamaJapan
  5. 5.Department of HematologyToranomon HospitalTokyoJapan
  6. 6.Department of HematologyUniversity of TsukubaTsukubaJapan

Personalised recommendations